Background: The objective of this study was to develop and analytically validate a
in captivity. The disease has been deemed to be endemic, with the reported prevalence ranging from 28% to 60% in the laboratory setting. 3 Chronic lymphocytic enteritis (CLE) is associated with chronic progressive weight loss in adults despite a good appetite, failure to thrive in juveniles. Diarrhea may or may not be present. The only consistent clinical pathological abnormalities are a mild anemia and hypoproteinemia. 3, 4 The disease is often terminal with affected marmosets either dying of being euthanized. The current gold standard for diagnosis is necropsy.
The development of a noninvasive test that may allow early antemortem diagnosis would facilitate screening and removal of affected marmosets before they are enrolled in research trials or breeding programs, thereby reducing the impact of this disease. Given that hypoproteinemia, particularly hypoalbuminemia, has been reported consistently in marmosets with chronic inflammation of the intestinal tract, we hypothesize this hypoproteinemia may be due to an intestinal loss of protein as seen in other species with inflammatory bowel disease. The gold standard for detecting gastrointestinal protein loss is the excretion of 51 Cr-albumin in feces, which is not feasible as a routine diagnostic test given the radiation hazards involved.
Alpha 1 -proteinase inhibitor (α 1 -PI) is a serum protein produced by the liver that is only lost in minimal quantities into the GI tract during health. Given the similar molecular weight to albumin, it is lost into the intestinal tract at a similar rate as is albumin. However, unlike albumin, it is resistant to degradation by digestive enzymes and bacteria within the intestinal lumen. Intact fecal α 1 -PI can be detected by immunoassays and have been employed to detect increased enteric protein loss in humans, 5 dogs, 6 and cats. 7 In dogs with protein-losing enteropathy, increased fecal α 1 -PI concentrations are thought to precede hypoalbuminemia. Assays are species specific and do not cross-react. 8 Recently, we described the purification and partial characterization of marmoset α 1 -PI from marmoset serum.
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The aims of this study were to develop and analytically validate an RIA for the quantification of α 1 -PI in serum samples and fecal extracts from marmosets and to establish reference intervals for serum and fecal α 1 -PI concentrations in healthy marmosets.
| MATERIAL S AND ME THODS

| Marmoset serum and fecal samples
Serum and fecal samples previously submitted to the Gastrointestinal Laboratory for research testing, and serum harvested from common marmosets euthanized as part of routine colony management procedures stored at −80°C and shipped on the dry ice were used for assay development and analytical validation.
| Animals
A total of 30 marmosets from two research colonies of common marmosets accredited by the Association for Assessment and Marmosets at the BMAC were fed a purified diet (#TD.07148
Marmoset Diet, Harlan Teklad, Madison, WI), and a primate enrichment mixture consisting of nuts, seeds, and dried fruit from the same manufacturer, both of which were irradiated at the manufacturing plant. Marmosets at the SNPRC were on two diets, a commercial New World primate diet (Mazuri diet (AVP Callitrichid 5LK6) and also on the same purified diet (without irradiation) used at the BMAC.
Diet for marmosets at the SNPRC also included daily food enrichment, such as yogurt, fruits, and cheerios.
Blood was collected from femoral bleeds from nonanesthetized marmosets held in a restraint device to which they were habituated. Paired serum and naturally passed fecal samples were collected from each animal. As it has been demonstrated that fecal α 1 -PI concentrations can have day-to-day variations in dogs, and no data exist for the common marmoset, fecal samples were collected for three consecutive days from each animal. Fecal samples were collected as soon after defecation as possible in preweighed polypropylene tubes and stored at −80°C until they were shipped on dry ice.
| Extraction of fecal samples
Fecal samples were thawed, and then, the extraction was carried out using phosphate buffered saline supplemented with 5% newborn calf serum, 1% Triton X-100, and 0.25 mmol/L thimerosal in a 1:5 dilution using approximately 1.0 g wet weight of feces. The fecal samples were homogenized by vortexing for 20 minutes, then centrifuged for 20 minutes at 2100g and 5°C, and then, the supernatants [fecal extract] were collected using serum filters and were stored frozen at −80°C until analysis. This extraction is similar to the extraction described for the canine assay. 
| Purification of marmoset α 1 -PI
Marmoset alpha 1 -proteinase inhibitor was purified from marmoset serum by affinity chromatography, and ceramic hydroxyapatite chromatography as described previously. 
| Antibody production
Polyclonal antibodies were raised in New Zealand white rabbits using a commercial antibody production service (Express-Line PLUS protocol; Lampire Biological Laboratories, Pipersville, Pennsylvania, USA). Purified marmoset α 1 -PI in phosphate buffered saline was used as the antigen, and antiserum specificity was tested as previously published. 9 Antiserum obtained after the fourth booster injection was selected for the RIA procedure with a final dilution, of 1:5000.
| Dilution of serum samples
Serum samples were diluted 1:32 000 in radioimmunoassay buffer (RIAB, 0.05 mol/L sodium phosphate, with 0.02% (w/v) sodium azide and 0.5% (w/v) bovine serum albumin (pH 7.5)) for the RIA.
| Dilution of fecal samples
Previously stored fecal extracts were thawed and diluted 1:200 in RIAB for the RIA.
| Tracer Radioiodination
The tracer was produced by iodination of pure marmoset α 1 -PI with 125 I, using the chloramine T method. Test samples containing mα 1 -PI in concentrations greater than the working range of the assay were further diluted by a factor of 2 and re-assayed.
| Marmoset alpha 1 -proteinase inhibitor radioimmunoassay validation
The mα 1 -PI RIA was analytically validated by determining the lower limit of the assay, the linearity, accuracy, precision, and reproducibility by evaluating assay sensitivity, dilutional parallelism, spiking recovery, intra-assay variability, and interassay variability.
Serum and fecal samples were selected at random from the available samples, and efforts were made to ensure that they fell into different areas of the working range of the assay. Serum samples used for validation were generated from a pool of several samples because marmosets are significantly smaller than companion animals, and serum volumes greater than 0.5 mL were not available for most animals. The lower limit of the assay was deter- mean) × 100. Interassay variability or reproducibility of the assay was determined by analyzing 8 sera and 8 fecal extracts in 3 consecutive assays and calculating interassay coefficient of variation; CV % = (SD/mean) × 100. To evaluate whether there was a position effect within the assay (end-of-run effect), two samples were tested in the same run by analyzing each sample 24 times in the same assay, with 8 duplicates placed in the beginning, middle, and at the end of the same assay. Mean mα 1 -PI concentration calculated from these positions on the assay was compared using a Kruskal-Wallis test (rank sum) test.
| Reference interval determination
The reference interval for serum concentrations of marmoset Statistical analyses were performed using a statistical software program (GRAPHPAD prism software, GraphPad Software, Inc. La Jolla, CA, USA), and statistical significance was set at P < 0.05.
| RE SULTS
The lower limit of the assay was calculated to be 0.8 μg/L. O/E, observed/expected.
TA B L E 1 (Continued)
samples and were 1.0%, 1.1%, 2.6%, 3.2%, 3.3%, 3.8%, 4.8%, and 6.7% for fecal extracts (n = 8) (Table 4a,b) . No significant differences in mean α 1 -PI concentrations depending on position of samples in the assay were observed (P = 0.4128).
A reference interval for serum and fecal α 1 -proteinase inhibitor concentrations (3-day mean, 3-day maximum) in feces was calculated using the central 95 th percentile using serum and fecal samples from healthy control marmosets [ Table 5 , Figures 1-3] . The median coefficient of variation for fecal α 1 -proteinase inhibitor concentrations between the 3-day fecal samples was 21.4% (range: 2.9%-74.3%).
| D ISCUSS I ON
An RIA for the measurement of α 1 -PI in serum samples and fecal extracts from marmosets was successfully developed. The analytical TA B L E 2 Spiking recovery of a radioimmunoassay (RIA) for the measurement of (a) serum alpha 1 -proteinase inhibitor (α 1 -PI) and (b) fecal alpha 1 -proteinase inhibitor (α 1 -PI) concentrations in the common marmoset Two samples, one serum sample with an O/E of 123.0% and one fecal sample with an O/E of 132.7%, were outside the "acceptable" limits.
One limitation of the study was that while the lower and upper limits of detection were established, a quantifiable measure of the upper and lower limits of quantitation (ULOQ/LLOQ) of the assay was not. The LLOQ may have explained the minor failures in the dilutional linearity test (123.0% for serum and 132.7% for fecal extracts).
The coefficients of variability were relatively low for both intraand interassay variability the maximum being 10.6%, indicating that the assay is precise and reproducible and is well within the acceptable ranges of <15%. 11, 12 No effect of the position of samples on the run was detected in the assay. A relatively high coefficient of variation for fecal α 1 -proteinase inhibitor concentrations between the 3-day fecal samples was seen in the marmosets (median 21.4%, range 2.9%-74.3%). The reason for this is unknown; however, a similarly high CV has also been reported for dogs (median: 29.2%, range 0.0% to 102.0%). 15 One possible explanation for this could be the effect of water content, as the fecal samples were normalized to volume. This perhaps could have potentially been reduced by normalization to an independent variable like dry weight, and this was not further explored in this study.
TA B L E 3 Precision of the radioimmunoassay for (a) serum α 1 -proteinase and (b) fecal α 1 -proteinase inhibitor concentration in the common marmoset (intra-assay validation) As serum and fecal samples were not readily available, the stability of samples at different storage conditions was not studied. Sample collection and storage conditions used in dogs 15, 16 and cats 7 were presumed to be appropriate. As the samples were collected, stored, extracted, and assayed around the same time from the two marmoset colonies, we do not expect this to affect our reference interval; however, changes in serum concentrations have been reported in dogs where samples were stored over a period of 1 year.
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A limited number of samples were available to establish the serum and fecal reference intervals for mα 1 -PI. Given the small number of animals in the study, no attempts were made to make age-specific ref-
erence intervals, which may have been more appropriate as younger dogs are reported to have higher concentrations of fecal α 1 -PI. 15 While it would have been ideal to have 120 marmoset samples to establish the reference interval, this would not have been practical.
The newly revised Clinical and Laboratory Standards Institute's (CLSI)
document does describe establishing a reference interval for an analyte using a samples size of 20; however, it only permits two individuals to be outside the established reference interval. In our study, 4, 2, and 2, individuals were outside the established reference intervals for serum, 3-day mean fecal, and 3-day maximum fecal α 1 -PI concentrations, respectively. Hence, additional work may be needed to establish a more robust reference interval for serum α 1 -PI concentrations in the common marmoset using this assay.
Another limitation of this study was that the animals that were used to establish the reference interval were presumed to be healthy based on the absence of clinical signs; however, given how TA B L E 4 Reproducibility of the radioimmunoassay for (a) serum α 1 -proteinase and (b) fecal α 1 -proteinase inhibitor concentrations in the common marmoset (interassay validation) little is known about the disease, subclinical chronic lymphocytic enteritis cannot be ruled out as gastrointestinal biopsies were not available.
The RIA for the measurement of serum and fecal α 1 -PI concentrations in the common marmoset described here is sensitive, linear, accurate, precise, and reproducible. Further studies are needed to determine the utility of this test for diagnosing gastrointestinal disease, particularly CLE in the marmoset. 
